The estrogen-responsive B box protein (EBBP) restores retinoid sensitivity in retinoid-resistant cancer cells via effects on histone acetylation

Cancer Letters

Volumn 277, Issue 1, 2009, Pages 82-90

  Raif, Anna ^a   Marshall, Glenn M ^a,b   Bell, Jessica L ^a   Koach, Jessica ^a   Tan, Owen ^a   D'andreti, Carla ^a   Thomas, Wayne ^a   Sekyere, Eric ^a   Norris, Murray ^a   Haber, Michelle ^a   Kavallaris, Maria ^a   Cheung, Belamy B ^a  

^a CHILDREN S CANCER INSTITUTE AUSTRALIA FOR MEDICAL RESEARCH   (Australia)

^b SYDNEY CHILDREN'S HOSPITAL   (Australia)

Author keywords

EBBP; HDAC inhibitor; RAR ; Retinoid; TRIM protein

Indexed keywords

AZACITIDINE; CYCLIN D1; CYTOCHROME P450 26A1; ESTROGEN RESPONSIVE B BOX PROTEIN; HISTONE; HISTONE DEACETYLASE INHIBITOR; PROTEIN; RETINOIC ACID; RETINOIC ACID RECEPTOR BETA; RETINOIC ACID RECEPTOR BETA2; RETINOID; TRICHOSTATIN A; TRIPARTITE MOTIF PROTEIN; UNCLASSIFIED DRUG;

ACETYLATION; ARTICLE; BREAST CANCER; CANCER CELL; CANCER RESISTANCE; CELL GROWTH; CELL VIABILITY; DNA RESPONSIVE ELEMENT; DRUG SENSITIVITY; LUNG CANCER; PRIORITY JOURNAL;

ACETYLATION; APOPTOSIS; CELL LINE, TUMOR; CELL SURVIVAL; CYCLIN D1; CYTOCHROME P-450 ENZYME SYSTEM; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; HISTONES; HUMANS; NEOPLASMS; PHOSPHORYLATION; RECEPTORS, RETINOIC ACID; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTORS; TRETINOIN;

EID: 61849097812     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2008.11.030     Document Type: Article

References (37)

1. Chambon P. A decade of molecular biology of retinoic acid receptors. Faseb J. 10 (1996) 940-954
2. Treuting P.M., Chen L.I., Buetow B.S., Zeng W., Birkebak T.A., Seewaldt V.L., Sommer K.M., Emond M., Maggio-Price L., and Swisshelm K. Retinoic acid receptor beta2 inhibition of metastasis in mouse mammary gland xenografts. Br. Cancer Res. Treat. 72 (2002) 79-88
3. Cheung B., Yan J., Smith S.A., Nguyen T., Lee M., Kavallaris M., Norris M.D., Haber M., and Marshall G.M. Growth inhibitory retinoid effects after recruitment of retinoid X receptor beta to the retinoic acid receptor beta promoter. Int. J. Cancer 105 (2003) 856-867
4. James S.Y., Lin F., Kolluri S.K., Dawson M.I., and Zhang X.K. Regulation of retinoic acid receptor beta expression by peroxisome proliferator-activated receptor gamma ligands in cancer cells. Cancer Res. 63 (2003) 3531-3538
5. Gebert J.F., Moghal N., Frangioni J.V., Sugarbaker D.J., and Neel B.G. High frequency of retinoic acid receptor beta abnormalities in human lung cancer. Oncogene 6 (1991) 1859-1868
6. Liu Y., Lee M.O., Wang H.G., Li Y., Hashimoto Y., Klaus M., Reed J.C., and Zhang X. Retinoic acid receptor beta mediates the growth-inhibitory effect of retinoic acid by promoting apoptosis in human breast cancer cells. Mol. Cell Biol. 16 (1996) 1138-1149
7. Berard J., Laboune F., Mukuna M., Masse S., Kothary R., and Bradley W.E. Lung tumors in mice expressing an antisense RARbeta2 transgene. Faseb J. 10 (1996) 1091-1097
8. Qiu H., Zhang W., El-Naggar A.K., Lippman S.M., Lin P., Lotan R., and Xu X.C. Loss of retinoic acid receptor-beta expression is an early event during esophageal carcinogenesis. Am. J. Pathol. 155 (1999) 1519-1523
9. Xu X.C., Sneige N., Liu X., Nandagiri R., Lee J.J., Lukmanji F., Hortobagyi G., Lippman S.M., Dhingra K., and Lotan R. Progressive decrease in nuclear retinoic acid receptor beta messenger RNA level during breast carcinogenesis. Cancer Res. 57 (1997) 4992-4996
10. Cheung B., Hocker J.E., Smith S.A., Norris M.D., Haber M., and Marshall G.M. Favorable prognostic significance of high-level retinoic acid receptor beta expression in neuroblastoma mediated by effects on cell cycle regulation. Oncogene 17 (1998) 751-759
11. Bovenzi V., and Momparler R.L. Antineoplastic action of 5-aza-2'-deoxycytidine and histone deacetylase inhibitor and their effect on the expression of retinoic acid receptor beta and estrogen receptor alpha genes in breast carcinoma cells. Cancer Chemother. Pharmacol. 48 (2001) 71-76
12. Widschwendter M., Berger J., Hermann M., Muller H.M., Amberger A., Zeschnigk M., Widschwendter A., Abendstein B., Zeimet A.G., Daxenbichler G., and Marth C. Methylation and silencing of the retinoic acid receptor-beta2 gene in breast cancer. J. Natl. Cancer Inst. 92 (2000) 826-832
13. Huang M.E., Ye Y.C., Chen S.R., Chai J.R., Lu J.X., Zhoa L., Gu L.J., and Wang Z.Y. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 72 (1988) 567-572
14. Recchia F., Saggio G., Cesta A., Alesse E., Gallo R., Necozione S., and Rea S. Phase II randomized study of interleukin-2 with or without 13-cis retinoic acid as maintenance therapy in patients with advanced cancer responsive to chemotherapy. Anticancer Res. 25 (2005) 3149-3157
15. Boorjian S.A., Milowsky M.I., Kaplan J., Albert M., Cobham M.V., Coll D.M., Mongan N.P., Shelton G., Petrylak D., Gudas L.J., and Nanus D.M. Phase 1/2 clinical trial of interferon alpha2b and weekly liposome-encapsulated all-trans retinoic acid in patients with advanced renal cell carcinoma. J. Immunother. 30 (2007) 655-662
16. van der Burg B., van der Leede B.M., Kwakkenbos-Isbrucker L., Salverda S., de Laat S.W., and van der Saag P.T. Retinoic acid resistance of estradiol-independent breast cancer cells coincides with diminished retinoic acid receptor function. Mol. Cell Endocrinol. 91 (1993) 149-157
17. Petty W.J., Li N., Biddle A., Bounds R., Nitkin C., Ma Y., Dragnev K.H., Freemantle S.J., and Dmitrovsky E. A novel retinoic acid receptor beta isoform and retinoid resistance in lung carcinogenesis. J. Natl. Cancer Inst. 97 (2005) 1645-1651
18. Boorjian S., Tickoo S.K., Mongan N.P., Yu H., Bok D., Rando R.R., Nanus D.M., Scherr D.S., and Gudas L.J. Reduced lecithin: retinol acyltransferase expression correlates with increased pathologic tumor stage in bladder cancer. Clin. Cancer Res. 10 (2004) 3429-3437
19. Zhang C., and Duvic M. Treatment of cutaneous T-cell lymphoma with retinoids. Dermatol. Ther. 19 (2006) 264-271
20. Cras A., Darsin-Bettinger D., Balitrand N., Cassinat B., Soulie A., Toubert M.E., Delva L., and Chomienne C. Epigenetic patterns of the retinoic acid receptor beta2 promoter in retinoic acid-resistant thyroid cancer cells. Oncogene 26 (2007) 4018-4024
21. Liu H.L., Golder-Novoselsky E., Seto M.H., Webster L., McClary J., and Zajchowski D.A. The novel estrogen-responsive B-box protein (EBBP) gene is tamoxifen-regulated in cells expressing an estrogen receptor DNA-binding domain mutant. Mol. Endocrinol. 12 (1998) 1733-1748
22. Beer H.D., Munding C., Dubois N., Mamie C., Hohl D., and Werner S. The estrogen-responsive B box prote: a novel regulator of keratinocyte differentiation. J. Biol. Chem. 277 (2002) 20740-20749
23. Munding C., Keller M., Niklaus G., Papin S., Tschopp J., Werner S., and Beer H.D. The estrogen-responsive B box prote: a novel enhancer of interleukin-1beta secretion. Cell Death Differ. 13 (2006) 1938-1949
24. Cheung B.B., Bell J., Raif A., Bohlken A., Yan J., Roediger B., Poljak A., Smith S., Lee M., Thomas W.D., Kavallaris M., Norris M., Haber M., Liu H.L., Zajchowski D., and Marshall G.M. The estrogen-responsive B box protein is a novel regulator of the retinoid signal. J. Biol. Chem. 281 (2006) 18246-18256
25. Liu T., Bohlken A., Kuljaca S., Lee M., Nguyen T., Smith S., Cheung B., Norris M.D., Haber M., Holloway A.J., Bowtell D.D., and Marshall G.M. The retinoid anticancer signal: mechanisms of target gene regulation. Br. J. Cancer 93 (2005) 310-318
26. Pozzi S., Rossetti S., Bistulfi G., and Sacchi N. RAR-mediated epigenetic control of the cytochrome P450 Cyp26a1 in embryocarcinoma cells. Oncogene 25 (2006) 1400-1407
27. Sherr C.J., and Roberts J.M. Living with or without cyclins and cyclin-dependent kinases. Genes Dev. 18 (2004) 2699-2711
28. Minucci S., Horn V., Bhattacharyya N., Russanova V., Ogryzko V.V., Gabriele L., Howard B.H., and Ozato K. A histone deacetylase inhibitor potentiates retinoid receptor action in embryonal carcinoma cells. Proc. Natl. Acad. Sci. 94 (1997) 11295-11300
29. Sirchia S.M., Ren M., Pili R., Sironi E., Somenzi G., Ghidoni R., Toma S., Nicolo G., and Sacchi N. Endogenous reactivation of the RARbeta2 tumor suppressor gene epigenetically silenced in breast cancer. Cancer Res. 62 (2002) 2455-2461
30. Sonneveld E., van den Brink C.E., Tertoolen L.G., van der Burg B., and van der Saag P.T. Retinoic acid hydroxylase (CYP26) is a key enzyme in neuronal differentiation of embryonal carcinoma cells. Dev Biol. 213 (1999) 390-404
31. Ray W.J., Bain G., Yao M., and Gottlieb D.I. CYP26, a novel mammalian cytochrome P450, is induced by retinoic acid and defines a new family. J. Biol. Chem. 272 (1997) 18702-18708
32. White J.A., Beckett-Jones B., Guo Y.D., Dilworth F.J., Bonasoro J., Jones G., and Petkovich M. cDNA cloning of human retinoic acid-metabolizing enzyme (hP450RAI) identifies a novel family of cytochromes P450. J. Biol. Chem. 272 (1997) 18538-18541
33. Langton S., and Gudas L.J. CYP26A1 knockout embryonic stem cells exhibit reduced differentiation and growth arrest in response to retinoic acid. Dev Biol. 315 (2008) 331-354
34. Chang G.C., Hsu S.L., Tsai J.R., Liang F.P., Lin S.Y., Sheu G.T., and Chen C.Y. Molecular mechanisms of ZD1839-induced G1-cell cycle arrest and apoptosis in human lung adenocarcinoma A549 cells. Biochem. Pharmacol. 68 (2004) 1453-1464
35. Bardon S., Foussard V., Fournel S., and Loubat A. Monoterpenes inhibit proliferation of human colon cancer cells by modulating cell cycle-related protein expression. Cancer Lett. 181 (2002) 187-194
36. Nevins J.R., Leone G., DeGregori J., and Jakoi L. Role of the Rb/E2F pathway in cell growth control. J. Cell. Physiol. 173 (1997) 233-236
37. Weinberg R.A. The retinoblastoma protein and cell cycle control. Cell 81 (1995) 323-330